Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes

Part of paid clinical trials in Bethesda, Maryland.

Sponsor
Eli Lilly and Company
Study ID
NCT01724580
Status
Approved For Marketing

Conditions

  • Aicardi-Goutières Syndrome (AGS)
  • Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)
  • Juvenile Dermatomyositis (JDM)
  • Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI)

Eligibility Criteria

Sex
ALL
Age
6 Months - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The Requesting Physician/Investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Key Dates

Status verified
Jan 2025

Locations (2)

FacilityCityStateZIPSite coordinators
Translational Autoinflammatory Disease (TADS)BethesdaMaryland20892-
Children's Hospital of PhiladelphiaPhiladelphiaPennsylvania19104-

Find similar trials in Bethesda, MD

By research site
Translational Autoinflammatory Disease (TADS)· Bethesda, MDChildren's Hospital of Philadelphia· Philadelphia, PA

Related Studies